Partner Sharon Crane will participate in a panel titled "AI and Drug Development: IP Implications for Protecting AI Discoveries" at IPWatchdog's 2nd Live Annual Meeting taking place September 11-13, 2022, in Dallas, Texas. Sharon's panel will take place on September 12.
As with many industries, Artificial intelligence (AI) enabled solutions are revolutionizing every stage of the drug development process to accelerate it and improve its efficiency. As biopharmaceutical companies increasingly rely on AI, there is a real possibility that a drug substance, drug product, or a drug formulation soon will be invented by AI. If and when that happens, who owns the intellectual property for those inventions?
Patent Offices around the world, including the United States Patent and Trademark Office, have determined that an AI cannot be listed as an inventor. If AI-created inventions cannot be patented, will the biopharmaceutical companies be interested in pursuing inventions using AI to develop drug products?
The panel will tackle these and other complicated and thorny legal issues presented by the use of AI in the drug development process.
Please visit the event website for more information and to register.